Tecentriq 1200mg Injection

About

Tecentriq 1200mg Injection contains atezolizumab, a monoclonal antibody that functions as a programmed death-ligand 1 (PD-L1) blocking antibody, representing a significant advancement in cancer immunotherapy. It works by specifically binding to PD-L1 expressed on tumor cells and tumor-infiltrating immune cells, thereby preventing its interaction with both the PD-1 and B7.1 receptors on T-cells. This blockade effectively disarms the PD-L1/PD-1 pathway, which cancer cells often exploit to evade immune surveillance. By releasing this immune checkpoint inhibition, atezolizumab reactivates the patient's own T-cells, enabling them to recognize, target, and destroy cancer cells more effectively. Tecentriq is indicated for the treatment of various advanced cancers, including non-small cell lung cancer, urothelial carcinoma, triple-negative breast cancer, and hepatocellular carcinoma, offering durable responses in eligible patients.

Uses

• Non-small cell lung cancer (NSCLC)
• Urothelial carcinoma
• Triple-negative breast cancer
• Hepatocellular carcinoma

Directions For Use

Administered as an intravenous infusion by a healthcare professional. The infusion duration and frequency are determined by the specific indication.

Benefits

• Activates the body's immune system against cancer
• Improves overall survival in various cancers
• Offers a targeted immunotherapy approach
• Effective in patients with high PD-L1 expression
• Can be used as monotherapy or in combination
• May lead to durable responses

Side Effects

• Fatigue
• Nausea
• Diarrhea
• Decreased appetite
• Rash
• Pyrexia (fever)
• Arthralgia (joint pain)
• Infusion-related reactions
• Hypothyroidism
• Pneumonitis (lung inflammation)
• Colitis (colon inflammation)
• Hepatitis (liver inflammation)

Safety Measures

• Alcohol - No specific contraindication, but excessive alcohol may worsen fatigue or liver-related side effects; discuss with a doctor.
• Pregnancy - Tecentriq can cause fetal harm; effective contraception is required during treatment and for at least 5 months after the last dose.
• Breastfeeding - It is not recommended during breastfeeding due to potential harm to the infant; discontinue breastfeeding during treatment.
• Liver - Use with caution in patients with pre-existing liver conditions; monitor liver function tests regularly for immune-mediated hepatitis.
• Kidney - No specific dose adjustment is typically required for renal impairment, but caution is advised; monitor kidney function.
• Lung - Patients should be closely monitored for signs and symptoms of immune-mediated pneumonitis; discontinue if confirmed.

Disclaimer

MedEHub is committed to delivering reliable, expert-reviewd information to help consumers make informed health decisions. However, the content provided on this website is for informational purposes only and is not intended to replace professional medical advice, diagnosis or treatment.

Always consult your doctor for any medical concerns, and discuss your questions about health conditions or medications with a qualified healthcare professional. Do not ignore or delay seeking professional medical advice based on information found on Med E Hub.

Our goal is to complement, not replace, the essential doctor-patient relationship.